Acumen Capital likes NeuPath Health right now

Acumen Capital analyst Nick Corcoran has initiated coverage of NeuPath Health (NeuPath Health Stock Quote, Chart, News, Analysts, Financials TSXV:NPTH) with a “Buy” rating and a $0.95 target, saying the company is well positioned in a recession-resistant healthcare segment supported by rising demand for chronic pain treatment and an aging population.

As reported by the Globe and Mail, on April 14, Corcoran said NeuPath’s multi-disciplinary clinic model gives it a strong position in a market where demand continues to build. He also said the stock trades at an attractive valuation, at 3.2x his projected 2027 EV/Adjusted EBITDA versus a peer-group average of 9.6x.

The initiation followed NeuPath’s fourth-quarter and full-year 2025 results, reported March 26. The company posted fourth-quarter revenue of $22.1-million, up 17% year over year, while Adjusted EBITDA rose nine per cent to $1.0-million, marking its 28th consecutive quarter of positive Adjusted EBITDA.

For full-year 2025, revenue increased 20% to $87.2-million and Adjusted EBITDA climbed 56% to $6.0-million. NeuPath ended the year with $4.5-million in cash and cash equivalents and $6.2-million in interest-bearing long-term debt.

CEO Joe Walewicz said the company delivered strong operating results in 2025 by serving more patients and adding new services, while president and incoming CEO Stephen Lemieux said NeuPath expects continued growth and margin improvement in 2026 as it expands locations and broadens access to procedures such as Arthrosamid.

-30-